CN118028155B - Novel probiotics, fermented coconut water metaplasia and application thereof in poultry feed additive - Google Patents
Novel probiotics, fermented coconut water metaplasia and application thereof in poultry feed additive Download PDFInfo
- Publication number
- CN118028155B CN118028155B CN202410122547.2A CN202410122547A CN118028155B CN 118028155 B CN118028155 B CN 118028155B CN 202410122547 A CN202410122547 A CN 202410122547A CN 118028155 B CN118028155 B CN 118028155B
- Authority
- CN
- China
- Prior art keywords
- coconut water
- ms2c
- lactobacillus
- fermentation
- strain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 235000020415 coconut juice Nutrition 0.000 title claims abstract description 133
- 239000006041 probiotic Substances 0.000 title claims abstract description 79
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 79
- 244000144977 poultry Species 0.000 title claims abstract description 16
- 239000003674 animal food additive Substances 0.000 title claims abstract description 14
- 206010054949 Metaplasia Diseases 0.000 title description 15
- 230000015689 metaplastic ossification Effects 0.000 title description 15
- 241000287828 Gallus gallus Species 0.000 claims abstract description 85
- 235000013330 chicken meat Nutrition 0.000 claims abstract description 84
- 238000000855 fermentation Methods 0.000 claims abstract description 73
- 230000004151 fermentation Effects 0.000 claims abstract description 72
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 37
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 37
- 230000000529 probiotic effect Effects 0.000 claims abstract description 35
- 241001465754 Metazoa Species 0.000 claims abstract description 33
- 241000186660 Lactobacillus Species 0.000 claims abstract description 31
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 31
- 238000011084 recovery Methods 0.000 claims abstract description 30
- 208000004232 Enteritis Diseases 0.000 claims abstract description 29
- 241000235342 Saccharomycetes Species 0.000 claims abstract description 23
- 235000013594 poultry meat Nutrition 0.000 claims abstract description 15
- 238000004321 preservation Methods 0.000 claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims description 77
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 66
- 239000004310 lactic acid Substances 0.000 claims description 33
- 235000014655 lactic acid Nutrition 0.000 claims description 33
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 23
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 19
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 19
- 235000013406 prebiotics Nutrition 0.000 claims description 19
- 150000001875 compounds Chemical class 0.000 claims description 17
- 239000002131 composite material Substances 0.000 claims description 16
- 230000012010 growth Effects 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 15
- 239000002054 inoculum Substances 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 241000271566 Aves Species 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 244000060011 Cocos nucifera Species 0.000 abstract description 25
- 235000013162 Cocos nucifera Nutrition 0.000 abstract description 25
- 230000009286 beneficial effect Effects 0.000 abstract description 18
- 238000012545 processing Methods 0.000 abstract description 10
- 239000006227 byproduct Substances 0.000 abstract description 7
- 239000002699 waste material Substances 0.000 abstract 1
- 230000000968 intestinal effect Effects 0.000 description 50
- 238000012360 testing method Methods 0.000 description 32
- 230000000694 effects Effects 0.000 description 30
- 208000012876 acute enteritis Diseases 0.000 description 29
- 239000002207 metabolite Substances 0.000 description 28
- 238000012216 screening Methods 0.000 description 25
- 239000003833 bile salt Substances 0.000 description 23
- 238000002474 experimental method Methods 0.000 description 23
- 238000004458 analytical method Methods 0.000 description 21
- 210000001035 gastrointestinal tract Anatomy 0.000 description 20
- 239000001963 growth medium Substances 0.000 description 20
- 210000002966 serum Anatomy 0.000 description 19
- 239000002253 acid Substances 0.000 description 18
- 229920003045 dextran sodium sulfate Polymers 0.000 description 18
- 230000004083 survival effect Effects 0.000 description 18
- 230000000844 anti-bacterial effect Effects 0.000 description 16
- 210000004534 cecum Anatomy 0.000 description 13
- 238000011081 inoculation Methods 0.000 description 13
- 244000005700 microbiome Species 0.000 description 12
- 241000701474 Alistipes Species 0.000 description 11
- 229930182843 D-Lactic acid Natural products 0.000 description 11
- JVTAAEKCZFNVCJ-UWTATZPHSA-N D-lactic acid Chemical compound C[C@@H](O)C(O)=O JVTAAEKCZFNVCJ-UWTATZPHSA-N 0.000 description 11
- 229940022769 d- lactic acid Drugs 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 8
- 241001112693 Lachnospiraceae Species 0.000 description 8
- 244000052616 bacterial pathogen Species 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 102000003814 Interleukin-10 Human genes 0.000 description 7
- 108090000174 Interleukin-10 Proteins 0.000 description 7
- 238000012258 culturing Methods 0.000 description 7
- 230000002354 daily effect Effects 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 230000037353 metabolic pathway Effects 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 108020004465 16S ribosomal RNA Proteins 0.000 description 6
- 241000755889 Christensenellaceae Species 0.000 description 6
- 102100037850 Interferon gamma Human genes 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 6
- 108090001005 Interleukin-6 Proteins 0.000 description 6
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 6
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000006378 damage Effects 0.000 description 6
- 230000015784 hyperosmotic salinity response Effects 0.000 description 6
- 235000013372 meat Nutrition 0.000 description 6
- 230000000813 microbial effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 235000000346 sugar Nutrition 0.000 description 6
- 229940116269 uric acid Drugs 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 5
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 5
- 241000191967 Staphylococcus aureus Species 0.000 description 5
- 230000002596 correlated effect Effects 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 230000007413 intestinal health Effects 0.000 description 5
- 238000009630 liquid culture Methods 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 241000186000 Bifidobacterium Species 0.000 description 4
- 239000002028 Biomass Substances 0.000 description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 4
- 241000607142 Salmonella Species 0.000 description 4
- 235000004279 alanine Nutrition 0.000 description 4
- 230000003110 anti-inflammatory effect Effects 0.000 description 4
- 229940093761 bile salts Drugs 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 238000010219 correlation analysis Methods 0.000 description 4
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 4
- VEGXETMJINRLTH-BOZYPMBZSA-N gentamycin C1a Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N VEGXETMJINRLTH-BOZYPMBZSA-N 0.000 description 4
- 150000002327 glycerophospholipids Chemical class 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 208000028774 intestinal disease Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 108010089148 polymyxin B2 Proteins 0.000 description 4
- SGPYLFWAQBAXCZ-RUDZPDEXSA-N polymyxin B2 Polymers N1C(=O)[C@H](CCN)NC(=O)[C@@H](NC(=O)[C@H](CCN)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)CCCCC(C)C)CCNC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1CC1=CC=CC=C1 SGPYLFWAQBAXCZ-RUDZPDEXSA-N 0.000 description 4
- 238000000513 principal component analysis Methods 0.000 description 4
- 230000008439 repair process Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 206010015548 Euthanasia Diseases 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 241000186840 Lactobacillus fermentum Species 0.000 description 3
- 241001352589 Lactococcus taiwanensis Species 0.000 description 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 3
- CZCIKBSVHDNIDH-NSHDSACASA-N N(alpha)-methyl-L-tryptophan Chemical compound C1=CC=C2C(C[C@H]([NH2+]C)C([O-])=O)=CNC2=C1 CZCIKBSVHDNIDH-NSHDSACASA-N 0.000 description 3
- CZCIKBSVHDNIDH-UHFFFAOYSA-N Nalpha-methyl-DL-tryptophan Natural products C1=CC=C2C(CC(NC)C(O)=O)=CNC2=C1 CZCIKBSVHDNIDH-UHFFFAOYSA-N 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000008272 agar Substances 0.000 description 3
- 235000003704 aspartic acid Nutrition 0.000 description 3
- 230000003385 bacteriostatic effect Effects 0.000 description 3
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 3
- 229940041514 candida albicans extract Drugs 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000011248 coating agent Substances 0.000 description 3
- 230000009266 disease activity Effects 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 235000013922 glutamic acid Nutrition 0.000 description 3
- 239000004220 glutamic acid Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 210000004347 intestinal mucosa Anatomy 0.000 description 3
- 229940012969 lactobacillus fermentum Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 3
- 229960003987 melatonin Drugs 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000006872 mrs medium Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 238000005457 optimization Methods 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 235000021391 short chain fatty acids Nutrition 0.000 description 3
- 150000004666 short chain fatty acids Chemical class 0.000 description 3
- 239000012138 yeast extract Substances 0.000 description 3
- JVTAAEKCZFNVCJ-UWTATZPHSA-M (R)-lactate Chemical compound C[C@@H](O)C([O-])=O JVTAAEKCZFNVCJ-UWTATZPHSA-M 0.000 description 2
- KMXXSJLYVJEBHI-UHFFFAOYSA-N 3-guanidinopropanoic acid Chemical compound NC(=[NH2+])NCCC([O-])=O KMXXSJLYVJEBHI-UHFFFAOYSA-N 0.000 description 2
- -1 ALISTIPES Chemical class 0.000 description 2
- 241000606125 Bacteroides Species 0.000 description 2
- 241000222290 Cladosporium Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 241000194032 Enterococcus faecalis Species 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 240000001046 Lactobacillus acidophilus Species 0.000 description 2
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 2
- 241000186779 Listeria monocytogenes Species 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- JWGGSJFIGIGFSQ-UHFFFAOYSA-N N-dodecanoylglycine Chemical compound CCCCCCCCCCCC(=O)NCC(O)=O JWGGSJFIGIGFSQ-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 101001077374 Oryza sativa subsp. japonica UMP-CMP kinase 3 Proteins 0.000 description 2
- URLKBWYHVLBVBO-UHFFFAOYSA-N Para-Xylene Chemical group CC1=CC=C(C)C=C1 URLKBWYHVLBVBO-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108010040201 Polymyxins Proteins 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 241000607768 Shigella Species 0.000 description 2
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000037354 amino acid metabolism Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 2
- 229940093265 berberine Drugs 0.000 description 2
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 2
- 210000000941 bile Anatomy 0.000 description 2
- 208000027503 bloody stool Diseases 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940032049 enterococcus faecalis Drugs 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000013401 experimental design Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003736 gastrointestinal content Anatomy 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000035861 hematochezia Diseases 0.000 description 2
- 238000007490 hematoxylin and eosin (H&E) staining Methods 0.000 description 2
- 238000012165 high-throughput sequencing Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 150000002430 hydrocarbons Chemical class 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 210000003405 ileum Anatomy 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000002490 intestinal epithelial cell Anatomy 0.000 description 2
- 230000006799 invasive growth in response to glucose limitation Effects 0.000 description 2
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 2
- 230000000877 morphologic effect Effects 0.000 description 2
- 229940094933 n-dodecane Drugs 0.000 description 2
- 238000012803 optimization experiment Methods 0.000 description 2
- 238000010239 partial least squares discriminant analysis Methods 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 238000004080 punching Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 238000011218 seed culture Methods 0.000 description 2
- 239000001632 sodium acetate Substances 0.000 description 2
- 235000017281 sodium acetate Nutrition 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009974 thixotropic effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- YWYZEGXAUVWDED-UHFFFAOYSA-N triammonium citrate Chemical compound [NH4+].[NH4+].[NH4+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YWYZEGXAUVWDED-UHFFFAOYSA-N 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000035899 viability Effects 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- KVNPSKDDJARYKK-JTQLQIEISA-N 5-methoxytryptophan Chemical compound COC1=CC=C2NC=C(C[C@H](N)C(O)=O)C2=C1 KVNPSKDDJARYKK-JTQLQIEISA-N 0.000 description 1
- 241001135163 Arcobacter Species 0.000 description 1
- 241001112741 Bacillaceae Species 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 229920002749 Bacterial cellulose Polymers 0.000 description 1
- 241001105998 Bacteroides dorei Species 0.000 description 1
- 101000798100 Bos taurus Lactotransferrin Proteins 0.000 description 1
- 241001465180 Botrytis Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 241000205236 Desulfurococcus Species 0.000 description 1
- 101100136092 Drosophila melanogaster peng gene Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 description 1
- 238000003794 Gram staining Methods 0.000 description 1
- 241000544058 Halophila Species 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 101001097860 Lithospermum erythrorhizon Phenylalanine ammonia-lyase 1 Proteins 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 241001602876 Nata Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010061481 Renal injury Diseases 0.000 description 1
- 241000192031 Ruminococcus Species 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 230000028654 Type IV pili-dependent aggregation Effects 0.000 description 1
- 208000023505 abnormal feces Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000005016 bacterial cellulose Substances 0.000 description 1
- 239000007640 basal medium Substances 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940072440 bovine lactoferrin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000034303 cell budding Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000006727 cell loss Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 210000003746 feather Anatomy 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000012262 fermentative production Methods 0.000 description 1
- 235000021107 fermented food Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 108010014487 geranylpyrophosphate olivetolate geranyltransferase Proteins 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 230000008944 intestinal immunity Effects 0.000 description 1
- 230000010226 intestinal metabolism Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000001630 jejunum Anatomy 0.000 description 1
- 230000008463 key metabolic pathway Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000037806 kidney injury Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000008558 metabolic pathway by substance Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033458 reproduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000002864 sequence alignment Methods 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 235000011046 triammonium citrate Nutrition 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000007222 ypd medium Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/12—Animal feeding-stuffs obtained by microbiological or biochemical processes by fermentation of natural products, e.g. of vegetable material, animal waste material or biomass
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
- A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
- A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K10/00—Animal feeding-stuffs
- A23K10/30—Animal feeding-stuffs from material of plant origin, e.g. roots, seeds or hay; from material of fungal origin, e.g. mushrooms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/70—Feeding-stuffs specially adapted for particular animals for birds
- A23K50/75—Feeding-stuffs specially adapted for particular animals for birds for poultry
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/16—Yeasts; Culture media therefor
- C12N1/165—Yeast isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
- C12R2001/25—Lactobacillus plantarum
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
- C12R2001/85—Saccharomyces
- C12R2001/865—Saccharomyces cerevisiae
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Animal Husbandry (AREA)
- Public Health (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Physiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Birds (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Epidemiology (AREA)
- Sustainable Development (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention provides a novel probiotic, fermented coconut water metazoan and application thereof in a feed additive for poultry, wherein the probiotic lactobacillus is Lactiplantibacillus plantarum MS c, and the preservation number is GDMCC No:64184 the probiotic yeast is Saccharomyces CEREVISIAE Y301, accession number GDMCC No:64183 and then lactobacillus MS2c and/or saccharomycete Y301 are used as strains to ferment coconut water to prepare the feed additive which is beneficial to self-healing recovery of enteritis of poultry, especially Wenchang chickens. The invention better utilizes the resource characteristics and component characteristics of the coconut water which is a byproduct of the coconut processing industry, realizes low-cost high-density fermentation culture of excellent probiotics, reduces waste and protects the environment according to local conditions, and achieves the purpose of green culture.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and relates to novel probiotics, fermented coconut water metazoan and application thereof in a feed additive for poultry.
Background
Wenchang chickens are indigenous characteristic chicken species in Hainan, are also excellent varieties in yellow feather chickens, and are required to be fattened due to unique 'white cutting chicken' making and eating modes, so that the grown-up chickens are required to be square and round in shape, tender in meat quality and long in fattening, the time for marketing is longer, generally more than 100 days, the risk of chicken infection of enteritis is increased compared with other chickens, and the environment-friendly breeding mode which is favorable for intestinal health and immunity is more urgent for using microbial preparations such as probiotics.
Coconut (Cocos nucifera l.) is one of the important commercial crops in the south of the sea, and because of its natural green, unique and delicious nature, coconut related products are continuously in hot sale and in short supply. The coconut processing products in the past mainly comprise coconut meat (solid endosperm of coconut), and the products comprise coconut juice, coconut slurry, coconut oil, coconut sugar, coconut chips and the like, and the coconut water is a byproduct of coconut shell breaking and meat taking, and belongs to the liquid endosperm part. In Hainan, enterprises for breaking shells of coconuts to obtain meat and supply the coconuts to downstream coconut meat processing are very common, and mainly used are raw coconuts imported from southeast Asia, and almost all of 20 hundred million coconuts consumed by annual processing adopt a traditional manual shell breaking mode, so that coconut water is in a state of scattered and inconvenient collection and inconvenient centralized storage when released from individual coconuts, and therefore, the coconut water after coconut meat is obtained in the coconut processing industry is often a byproduct which is not fresh enough, loses freshness and can not be drunk any more, and can only be processed and utilized industrially. Over ten years ago, this coconut water was used for the fermentative production of coconut (nata de coco, a bacterial cellulose) and the byproduct coconut water produced during this process was still to be utilized for high value processing due to the fact that the traditional technology in the real industry was dominant.
Disclosure of Invention
The invention aims to provide novel probiotics, fermented coconut water metazoan and application thereof in poultry feed additives, and based on high-value utilization of less fresh and less fresh coconut water, probiotics with excellent probiotic characteristics and suitable for intestinal health of poultry are screened based on a replacement strategy of poultry cultivation, and the probiotics are combined with local coconut resources and fermented to prepare the high-activity coconut water metazoan, so that the high-biomass coconut water fermented feed additives are prepared, and a novel approach is explored for green efficient cultivation of poultry, particularly Wenchang chickens.
In order to achieve the above purpose, the invention adopts the following technical scheme:
The invention provides a novel probiotic lactic acid bacteria, which is named Lactiplantibacillus plantarum MS c and has the preservation number of GDMCC No:64184.
The invention also provides a novel probiotic microzyme, named Saccharomyces CEREVISIAE Y301, accession number GDMCC No:64183.
The invention also provides a prebiotic of the coconut water fermented by probiotics, which comprises a lactic acid bacteria fermentation coconut water metazoan taking lactic acid bacteria MS2c single bacteria as a fermentation strain, a yeast fermentation coconut water metazoan taking yeast Y301 single bacteria as a fermentation strain, and a compound bacterial strain fermentation coconut water metazoan taking lactic acid bacteria MS2c and yeast Y301 together as fermentation strains; the lactobacillus MS2c has a preservation number of GDMCC No:64184; the preservation number of the saccharomycete Y301 is GDMCC No:64183.
The invention also provides a preparation method of the prebiotics after the coconut water is fermented by probiotics, which comprises the following steps: simultaneously inoculating lactobacillus MS2c and saccharomycete Y301 according to the following lactobacillus: the yeast is in a ratio of 1:2, 4 percent of total inoculum size is removed from the compound strain to ferment coconut water, the fermentation temperature is 33-37 ℃, and the fermentation time is 24-30 hours; the lactobacillus MS2c has a preservation number of GDMCC No:64184; the preservation number of the saccharomycete Y301 is GDMCC No:64183.
The invention also provides a feed additive for poultry, which comprises the probiotic fermented coconut water metaplasia.
The invention also provides application of the prebiotics obtained by fermenting coconut water with the probiotics in the growth of poultry and the promotion of enteritis self-healing recovery.
Further, the lactobacillus fermented coconut water metagen can relieve the increase of IL-6, IL-10, TNF-alpha, IFN-gamma, D-lactic acid, uric acid, GPT and GOT contents caused by enteritis in serum, the lactobacillus fermented coconut water metagen can relieve the increase of TNF-alpha, IFN-gamma and D-lactic acid contents caused by enteritis in serum, and the compound strain fermented coconut water metagen can relieve the increase of IL-6, IL-10, IFN-gamma and D-lactic acid contents caused by enteritis in serum.
Further, the yeast fermented coconut water metaplasia and the lactic acid bacteria fermented coconut water metaplasia can improve intestinal villus structure and intestinal wall thickness and recover damaged intestinal mucosa.
Further, the yeast fermented coconut water metazoan is capable of modulating amino acid metabolism, reducing the abundance of potential pathogenic bacteria including alanine, aspartic acid, and glutamic acid, increasing the abundance of potential beneficial bacteria including achalamin, deoxynucleotide, lauroyl glycine, guanidinopropionic acid, and methyltryptophan, increasing the abundance of anti-inflammatory and anti-inflammatory compounds including ALISTIPES, the potential beneficial bacteria including chaetoceraceae Lachnospiraceae, and improving the growth rate of birds; the lactic acid bacteria fermented coconut water metazoan can regulate glycerophospholipid metabolic pathway, remodel intestinal flora structure, reduce abundance of potential pathogenic bacteria, increase abundance of potential beneficial bacteria, inhibit production of potential carcinogen epsilon-caprolactam and cause production of specific intestinal metabolites, wherein the potential pathogenic bacteria comprise ALISTIPES genus, and the potential beneficial bacteria comprise lactobacillus plantarum, krigine Teng Senshi family CHRISTENSENELLACEAE, LACHNOSPIRACEAE and bifidobacterium ragon; the compound strain fermented coconut water metazoan can enhance the growth performance of poultry, relieve intestinal wall damage and increase the abundance of specific intestinal metabolites, thereby relieving enteritis symptoms; the specific intestinal metabolites include glyceride CDP-DG, gentamicin C and polymyxin B2.
In the invention, the poultry is preferably Wenchang chicken.
The invention has the beneficial effects that:
The present invention discusses the possibility of using coconut water as a probiotic medium to produce a metaproduct. In addition, the invention also researches the effectiveness of the probiotic products in promoting recovery of the acute enteritis of Wenchang chickens. This study not only demonstrates the impact and mechanism of fermentation of probiotics in coconut water on the self-recovery of chickens suffering from acute enteritis, but also provides a valuable route to utilizing non-fresh, ineligible coconut water.
The invention firstly screens lactobacillus from the intestinal canal of the indigenous Wenchang chicken, screens saccharomycetes from natural fermentation coconut water in a processing plant, obtains a plurality of high-activity strains with excellent properties through a large number of probiotics and antibacterial activity tests, screens a strain of saccharomyces cerevisiae Y301 and a strain of lactobacillus plantarum MS2c which can grow rapidly in the coconut water and have excellent probiotics, respectively cultures lactobacillus and saccharomycetes by-product coconut water as culture matrixes, simultaneously respectively cultures the strains at high density through fermentation condition optimization, carries out fermentation culture of compound strains, obtains a metaplasia product of the metaplasia products of the high-activity thalli and the metabolites of the metaplasia products, namely the high-activity fermentation coconut water metaplasia products, and is used as a feed additive to irrigate the Wenchang chicken suffering from acute enteritis, and has obvious promotion effects on growth performance of the Wenchang chicken, biochemical and immune indexes and self-healing recovery of enteritis. The invention better utilizes the resource characteristics and component characteristics of the byproduct coconut water, realizes the high-density fermentation culture of excellent probiotics, prepares the feed additive which is favorable for the enteritis self-healing recovery of Wenchang chickens, realizes the local material-taking protection and resource utilization, and achieves the purpose of green cultivation. The invention is simple, convenient, efficient, ingenious and scientific, and is a new idea for carefully screening, developing and innovatively applying according to local conditions.
Drawings
FIG. 1 shows the survival rate of the strain of example 1 of the present invention in a pH2.5 and 0.3% bile salt environment for 3 hours, and the different cases indicate differences in tolerance to pH2.5 and 0.3% bile salt concentration (P < 0.05) between the different strains.
FIG. 2 shows the surface hydrophobicity and self-polymerizing ability of the strains of example 1 of the present invention, different cases indicating differences in group between different strains (P < 0.05).
FIG. 3 shows the antibacterial activity of the lactic acid bacteria against Salmonella bacteria of example 1 of the present invention, the letters being quite different representing a significant difference (p < 0.05).
FIG. 4 shows the bacteriostatic activity of the lactic acid bacteria against E.coli in example 1 of the present invention, the letters being quite different representing a significant difference (p < 0.05).
FIG. 5 shows that the size of the inhibition zone of the lactic acid bacteria against Staphylococcus aureus in example 1 of the present invention, the letters are completely different, representing the significant difference (p < 0.05).
FIG. 6 shows the acid-resistant survival rate of rescreened lactic acid bacteria of example 1 of the present invention, capital letters are the differences between groups, lowercase letters are the differences within groups, and complete differences in letters represent significant differences (p < 0.05).
FIG. 7 shows the bile salt-resistant viability of rescreened lactic acid bacteria of example 1 of the invention, capital letters being the difference between groups and lowercase letters being the difference within groups, the letters being completely different representing significant differences (p < 0.05).
FIG. 8 is a graph showing the effect of different amounts of each component added on the number of living MS2c bacteria in example 1 of the present invention, and the difference is remarkable (p < 0.05) as the letters are completely different.
FIG. 9 is a microscopic image of several yeasts of different morphologies and a single colony morphology according to example 2 of the present invention.
FIG. 10 shows the results of comparing the viable count of each candidate yeast in coconut water in example 2 of the present invention.
FIG. 11 shows acid resistant survival of the re-screened yeasts in example 2 of the present invention.
FIG. 12 shows the bile salt-tolerant survival of the rescreened yeasts of example 2 of the present invention.
FIG. 13 is a graph showing the relationship between the inoculation ratio and the viable count of the composite fermentation in example 3 of the present invention.
FIG. 14 is a graph showing the relationship between the inoculation sequence and the viable count of the composite fermentation in example 3 of the present invention.
FIG. 15 is a graph showing the relationship between the inoculum size and the viable count of the composite fermentation in example 3 of the invention.
FIG. 16 shows the number of viable bacteria of each of the single strain fermentation and the composite strain fermentation in example 3 of the present invention.
FIG. 17 is a schematic diagram showing the experimental design of the intervention of the prebiotics of the coconut water fermented by the probiotics on the acute enteritis chickens in the test example of the invention.
FIG. 18 shows the effect of probiotic fermented coconut water metazoan on the growth performance of acutely enteritis chickens in test cases of the invention, (a) average daily feed intake; (b) average daily body weight; (c) an average DAI disease activity index.
FIG. 19 shows the effect of fermented coconut water metazoan on serum immunobiochemical markers of acute enteritis chickens in a test example of the invention, (a) serum immunometric content profile; (b) serum biochemical index content map.
FIG. 20 is a graph showing the effect of prebiotic intervention on repair of acute enteritis chicken intestinal wall injury after fermentation of coconut water by probiotics in a test example of the invention; (left) morphological effect comparison of different magnifications of intestinal mucosa tissue; comparison of intestinal wall thickness (right).
FIG. 21 shows shannon index (a) and beta diversity (b) of chicken intestinal microbiome alpha diversity in test cases of the present invention.
FIG. 22 is a block diagram of the microbiome of the cecum content of chickens in a test case of the present invention.
FIG. 23 illustrates comparative analysis of the effect of post-fermentation coconut water metazoan intervention on the microbiota of the cecal content of each group of chickens, (C) CK1, CK2 and CK3; (D) CK1, CK2, and M2; (E) CK1, CK2 and Y3; (F) CK1, CK2, and MY5.
FIG. 24 is a principal component analysis plot between six groups and a partial least squares-discriminant analysis plot for comparison between each group and model groups, (a) a principal component analysis plot between six groups; (b) CK1 and CK2; (c) CK2 and CK3; (d) CK2 and M2; (e) CK2 and Y3; (f) CK2 and MY5.
FIG. 25 shows a topology of KEGG metabolic pathways, (left) M2 group, (right) Y3 group.
FIG. 26 shows a network analysis of the correlation between differential flora and differential metabolites in test cases of the invention, (a) shows a correlation analysis with the intervention of single plant MS2c fermented coconut water (group M2); (b) Related analysis under the intervention of single strain Y301 fermented coconut water (group Y3) is shown. (based on p <0.05 and correlation coefficient r > 0.4).
FIG. 27 illustrates the mechanisms of MS2c fermented coconut water intervention and Y301 fermented coconut water intervention to promote recovery from chicken colitis, (a) outlines the mechanism of correlation between differential flora, differential metabolites and biochemical immune indicators of MS2c intervention; (b) The mechanism of correlation between the differential flora, differential metabolites and biochemical immune index of Y301 intervention is outlined.
Detailed Description
In order to more clearly illustrate the present invention, the present invention will be described in further detail below with reference to examples and with reference to the accompanying drawings. It is to be understood by persons skilled in the art that the following detailed description is illustrative and not restrictive, and that this invention is not limited to the details given herein.
The research thought of the invention mainly comprises the following aspects:
Firstly, based on acid and bile salt resistance, bacteriostasis activity and the like, probiotic lactobacillus and saccharomycetes are widely screened, and then further re-screening is carried out on the condition that the rapid propagation in coconut water reaches high biomass, so as to obtain probiotic strains capable of growing vigorously in the coconut water.
And secondly, researching the process conditions of single-strain fermentation and composite-strain fermentation of the probiotics based on the coconut water matrix, and optimizing the composite fermentation process of the probiotics in the coconut water to obtain a high-activity fermented coconut water metaplasia product with the advantages of both the probiotics microzyme and the probiotic lactic acid bacteria.
Thirdly, taking the feed additive as a feed additive for poultry, and feeding the Wenchang chicken enteritis model by three fermented coconut water metazoans, and researching the effect of the fermented coconut water metazoans on self-healing recovery and the mechanism of the fermented coconut water metazoans on the intestinal flora structure and composition, the intestinal metabolite difference, the physiological biochemistry and immune indexes and the correlation relationship between the intestinal flora structure and composition and the physiological biochemistry and immune indexes.
Example 1 screening and identification of Lactobacillus plantarum MS2c
The strain has been deposited at the collection of microorganism strains (GDMCC) of Guangdong province at 12/24 of 2023 under the deposit number GDMCCNo:64184, deposit address: building 5, road 100, university, building 59, university of Guangzhou City martyr, university of Guangdong, institute of microorganisms, taxonomic designation: lactobacillus plantarum (Lactiplantibacillusplantarum).
Experimental material
1.1 Sieving, culturing and fermenting Experimental Material
And (5) taking intestinal contents for lactobacillus separation after bloodletting and slaughtering of the local domestic adult Wenchang chickens.
Coconut water: the mature coconut in the coconut processing factory is immediately filtered by two filter cloths of more than 400 meshes and more than 1000 meshes after being broken and taken, and is quickly placed at a low temperature of 3-4 ℃ for refrigeration. For preparing culture medium.
Other experimental materials such as tryptone, agar powder, etc. are all conventional experimental materials unless otherwise specified.
1.2 Preparation of Medium and Sterilization
MRS medium: 54g of MRS dry powder is added into distilled water 1L, stirred and heated until the MRS dry powder is completely dissolved, and the pH is natural and about 6.4. Is used as a seed culture medium for lactobacillus screening, preservation and fermentation.
LB medium: 10g of tryptone, 5g of yeast extract powder and 10g of sodium chloride are added with 1L of distilled water, stirred and heated until the mixture is completely dissolved, and the pH is natural. The strain is used as a strain seed culture medium for bacteriostasis experiment indication.
Coconut water basal medium: coconut water, and a refractive sugar degree of about 5.0-5.4 degrees Bx, and adding a glucose solution to adjust the sugar degree to 6.0 degrees Bx, and using the mixture as a fermentation basic culture medium.
1.2 To 1.5 percent of agar powder is added when the solid culture medium is prepared. All media were sterilized at 121℃for 15min.
1.3 Major instrumentation
And (3) a microscope: orinbas Inc., japan; high-speed refrigerated centrifuge: thermo company, germany; pure water meter: taiwan Ai Ke of china; colony analyzer (model MF 4) was from shanghai science and technology limited, china, and the enzyme-labeled instrument (model Synergy LX) was from united states BIOTEK, and the hand-held meter (model PAL-1) was from japan aiton.
Test methods and results
2.1 Screening and identification of lactic acid bacteria in the intestinal tract of Wenchang chickens in Hainan province
All experiments were performed in triplicate and the data are shown as mean ± SD. Carrying out data statistics analysis by adopting SPSS22 software; drawing by using Origin2019 software; significance was analyzed using one-way analysis of variance (ANOVA). The different letters on the bar graph represent significant differences (P < 0.05). 2.1.1 preliminary separation and purification of lactic acid bacteria
The sample Wenchang chicken is brought back to a laboratory, the blood is taken by pricking, the duodenum, the cecum and the ileum and the content are collected in a 50mL centrifuge tube, 25g of the cecum and the jejunum content are respectively diluted by 10 times with sterile physiological saline (0.85% w/v, pH 7.2-7.4) in an ultra clean bench, and homogenized for 20 minutes. The colony with large transparent ring of dissolved calcium is selected for streak purification by coating and separating on MRS plate containing 2% (w/v) CaCO 3 by dilution coating method, culturing at 37 ℃ for 48 hours, selecting colony with quick growth and large transparent ring for gram staining, selecting positive strain, and then carrying out thixotropic enzyme test. All G + and thixotropic strains are found to be straight, thick, rod-shaped or short-rod-shaped, and the two ends of the strain are straight or round, and are mostly arranged singly, in pairs or in short chain shape, so that the strain accords with the general characteristics of lactobacillus, and 11 strains are initially selected for subsequent screening through primary screening. 2.1.2 acid and bile salt resistance testing of Strain
Acid and bile tolerance is one of the important criteria for screening probiotic strains. The activated 11 primary screened test strains were centrifuged at 4500r/min for 10min, respectively, and the cells were washed twice with sterile Phosphate Buffered Saline (PBS), resuspended, and incubated at 37℃for 3h in MRS medium at pH 2.5 and MRS medium containing 0.3% (w/v) bile salts, respectively. Plate counts were performed at 0h and 3h, respectively, with reference to national standard GB 4789.2-2016, and survival rates were calculated to evaluate the acid and bile salt resistance of each strain.
As shown in FIG. 1, strains K111, MS2c, MZ2, MS2 and MS111 show good acid tolerance, the survival rate is close to or more than 100%, wherein the acid tolerance of the strain K111 is highest, and the survival rate is close to 120%; the bile salt tolerance of the strains MS2c, MZ2, S311, K111 and MS111, MY1 is significantly higher than that of other strains (P < 0.05), wherein the strain MS2c has the highest bile salt tolerance and the survival rate is 70.41%.2.1.3 cell surface hydrophobicity test of lactic acid bacteria
The surface hydrophobicity of bacteria can be indirectly evaluated for its ability to adhere to intestinal epithelial cells, and is generally high and generally has a high ability to adhere to intestinal mucosal cells, and is generally tested for hydrophobicity with the affinity of lactic acid bacteria for hydrocarbons. This example was measured using the cell adhesion hydrocarbon method with a slight modification. The test strain activation culture solution is centrifuged at 4500r/min for 10min, washed by PBS buffer solution for 2 times and resuspended in 3mL PBS, and the initial absorbance is controlled to OD 600 within the range of 0.6-0.8. 1mL of dimethylbenzene and n-dodecane are added into the bacterial suspension, the bacterial suspension is vortexed for 1-2min, is taken out after standing and warm bath for 15min at 37 ℃, is vortexed for 1-2min again, is subjected to standing for 1h, and the OD 600 of an upper organic phase is measured to calculate the surface hydrophobicity of the bacterial strain.
To comprehensively examine the performances of all strains and realize no screening, 11 strains are tested, and as shown in fig. 2, the surface hydrophobicity of the strain MS2c, which is shown by the paraxylene and n-dodecane solvent, is obviously higher than that of other strains (P < 0.05), which are respectively 43.82 percent and 54.12 percent; the surface hydrophobicity of the other strains is lower than 40%, wherein the surface hydrophobicity of the strain K111 and the surface hydrophobicity of the strain MS111 in two solvents are similar and are about 40% and about 20% respectively, so that the hydrophobicity of the strain MS2c is highest, and the strain K111, the strain MS111 and the strain S311 possibly have better adhesion to intestinal tracts and are hydrophobic times; other strains were very hydrophobic.
2.1.4 Automatic polymerization ability test of lactic acid bacteria
The ability of bacteria to colonise the gut and form their biofilms is inseparable, and the high self-polymerizability of the strains helps to form biofilms to protect their own activity. The self-polymerization capability of the lactobacillus has strain specificity, and different strains have larger difference. With a slight modification in reference (RAHMAN M,KIM W S,KUMURA H,et al.In vitro effects of bovine lactoferrin on autoaggregation ability and surface hydrophobicity of bifidobacteria[J].Anaerobe,2008,14(2):73-77.), the strain culture was centrifuged at 4500r/min for 10min, washed with PBS, resuspended, and after vortexing, the initial turbidity OD 600 was measured, and after standing at 37℃for 24h, the supernatant turbidity OD 600 was measured, and the self-polymerization percentage was calculated.
As shown in fig. 2, a difference was found in the autopolymerization ability of all strains, with the autopolymerization ability of strain MS2c still being highest, 88.52%, significantly higher than that of the other strains (P < 0.05); the strains K111, MS111, MZ2, MZ6 and S311 all have an autopolymerization force exceeding 60%, and also have good autopolymerization ability.
2.1.5 Antibacterial Activity test of lactic acid bacteria
The bacteriostasis ability of probiotics is particularly important, and as a probiotic strain for enteritis curing application, the probiotic strain must have good ability of inhibiting the growth of pathogenic bacteria, and the bacteriostasis test indicator used in the embodiment is common pathogenic bacteria, such as escherichia coli ECXT, salmonella SXS, staphylococcus aureus JH, listeria monocytogenes and pseudomonas aeruginosa, and the indicator is cultivated for 24 hours at the inoculation amount of 2% (v/v) in an LB culture medium at 37 ℃ for later use, and is slightly modified according to the agar diffusion method described by Muhammad et al. Adding the strain to be tested into MRS culture medium according to the inoculation amount of 2% (v/v), culturing at 37 ℃ for 24 hours to obtain a first-generation culture, activating again to obtain a second-generation culture, adding 0.5mL of indicator bacteria into a sterile empty culture dish, pouring LB agar culture medium cooled to about 50 ℃ after sterilization into the culture dish, quickly and fully mixing uniformly, cooling and solidifying, preparing holes by using a sterile puncher (6 mm), adding 70 mu L of activated 2-generation culture of the strain to be tested into each hole, culturing at 37 ℃ for 24 hours, and measuring the diameter (mm) of a transparent bacteriostasis ring.
For no screening, the 11 strains were all subjected to bacteriostasis capability test (see table 1), and the diameter of the bacteriostasis zone was found to be between 10.52 and 18.65mm, and significant differences exist. Wherein, the bacteria inhibition zones of the strains MS2c, K111 and MS111 on salmonella, staphylococcus aureus and escherichia coli are all obviously superior to other strains (P < 0.05); the bacteria inhibition zone of the strain MS2c on the listeria monocytogenes is obviously larger than that of other strains (P < 0.05); the bacteriostasis circle of the strains MS2c and K111 on the pseudomonas aeruginosa is obviously larger than that of other strains (P < 0.05); the strains MS2c, K111, MS111 and S311 have larger bacteriostasis circles for five indicator bacteria in a combined way, which indicates that the bacteria have wider bacteriostasis spectrums and better bacteriostasis capacity.
TABLE 1 antibacterial conditions of fermentation supernatants of Strain on five indicator bacteria
Note that: different lowercase letters indicate significant differences between the same column of data (P < 0.05), and the same letter indicates insignificant differences.
2.1.6 16S rDNA sequencing
Through the probiotic characteristic test, the 4 strains of lactic acid bacteria MS2c, K111, MS111 and S311 are found to have excellent performance, and then the molecular biological species identification of the 16S rDNA is carried out. Strain identification was done by Qingdao peng Xiang biotechnology Co., ltd, using 16S universal primers for amplification and sequencing analysis. Wherein the molecular sequence of the 16S rDNA gene of the strain MS2c is 1391bp, and the sequence of the molecular sequence is shown as SEQ ID NO. 1.
The results of the BLAST on-line analysis were compared with the gene sequences in NCBI database, and are shown in Table 2, wherein the homology of the strains MS2c, K111 and MS111 with Lactobacillus plantarum (Lactobacillus plantarum, which is designated Lactiplantibacillus plantarum recently) is highest, the homology of the strain S311 with enterococcus faecalis (Enterococcus faecalis) is highest, the homology and coverage percentage of all strains with the reference bacteria in the gene library are over 99%, and the E value is 0 (see Table 2).
Table 24 16S rDNA homology comparison analysis of strains
2.2 Comparison and rescreening of Excellent probiotics based on Strong bacteriostatic Activity
Candidate lactic acid bacteria: lactobacillus plantarum (Lactiplantibacillus plantarum) MS2c, MS111 and K111 obtained by the preliminary screening; screening and identifying antagonistic lactobacillus in natural fermented coconut water and antibacterial property [ J ]. Food research and development. 2021,42 (23) DOI: 10.12161/j.issn.1005-6521.2021.23.025.); lactobacillus acidophilus (Lactobacillus acidophilus) LA71, a commercial strain of probiotic bacteria, for control; W417-W421 are lactobacillus which is screened from coconut water after natural fermentation (more than 48 hours of standing fermentation in an open container at the temperature of 25-35 ℃) in coconut processing factories and is preliminarily confirmed, but the lactobacillus is not identified by species.
The SPSS21.0 software is adopted to carry out statistical analysis on experimental data, the average value of the experimental data is represented by +/-standard error, the F test is adopted to carry out difference significance analysis on the experimental result, P is smaller than 0.05 and represents the difference is significant, and P is smaller than 0.01 and represents the difference is extremely significant.
2.2.1 Strain and its activation and seed liquid preparation
Test strain: MS2c, MS111, K111, A32, W417 to W421, LA71
Indicator strain: coli ECXT, salmonella SXS, staphylococcus aureus JH
Taking frozen strain at-80 deg.C, and respectively culturing with MRS (lactic acid bacteria) or LB (indicator bacteria) liquid culture medium at 37 deg.C for two generations to make absorbance OD 600 reach about 0.8, and using as seed solution.
2.2.2 Antibacterial prescreening and tolerating rescreening
The bacteria with strong antibacterial activity are selected by performing antibacterial activity test on the 10 lactobacillus with different sources, and then acid and bile salt resistance are compared to re-screen out excellent probiotics with high probiotic characteristics for developing a chicken enteritis cure test.
(1) Antibacterial screening
And (3) carrying out in-vitro antibacterial activity test on 10 strains of lactic acid bacteria, and measuring the diameter of a bacteriostasis ring by adopting a perforation method.
Bacteriostasis test by punching method: adding 100 mu L (total viable count is about 10 5~106 cfu/mL) of indicator bacteria liquid into a flat plate, pouring and cooling to about 50 ℃ and 20mL of LB solid medium, rapidly and fully mixing, punching by a puncher after solidification, adding 80 mu L of test bacteria fermentation liquor into the hole, standing and culturing for 16-18h, observing a bacteriostasis result, and measuring the diameter of a bacteriostasis ring.
Strains with higher antibacterial activity are screened through antibacterial action on three pathogenic indicator bacteria, and as shown in figures 3-5, three lactic acid bacteria MS2c, A32 and MS111 have good antibacterial activity compared with a control strain LA 71. Wherein MS2c is significantly stronger than a32, also significantly stronger than LA71 strain (p < 0.05), and the three strains have a stronger inhibitory effect on gram-positive staphylococcus aureus (p < 0.05). MS111 and MS2c are Lactobacillus plantarum and A32 is Lactobacillus fermentum, so these three strains were selected for fermentation in coconut water for further screening.
(2) Acid-resistant and bile salt-resistant rescreening
Acid resistance experiment: the pH of the MRS culture solution was adjusted to 2.0, 3.0 and 4.0 with 1mol/L HCl solution, respectively. Three lactic acid bacteria to be compared are respectively inoculated into MRS liquid culture media with different pH values, and are cultured for 16 hours at 37 ℃, and OD 600 values are measured to calculate the survival rate.
Bile salt resistance experiment: three lactic acid bacteria to be compared are respectively inoculated into MRS liquid culture media with different bile salt concentrations (0, 0.3%, 0.6% and 0.9%), and are cultured for 16 hours at 37 ℃, and OD 600 is measured to calculate the survival rate.
The experimental results (as shown in fig. 6 and 7) show that the acid resistance of lactobacillus plantarum MS2c and MS111 is significantly higher than that of lactobacillus fermentum a32 (p < 0.05) under different pH environments. In terms of cholate resistance, the survival rate of MS2c is extremely higher than A32 and also is obviously higher than that of MS111 (p < 0.05) at three concentrations, three strains are comprehensively evaluated through antibacterial activity and acid-resistant cholate-resistant characteristics, and MS2c is selected as a preferred strain for subsequent further experiments. The fermentation culture condition of the strain in coconut water is optimized.
2.2.3 Optimization of fermentation conditions of high bacteriostatic Activity probiotics in coconut Water
And (3) selecting the experimental condition with the highest viable count by carrying out optimization experiments on different culture medium components.
Strain density determination: the strain was cultured at MRS 37℃for 18 hours. 200. Mu.L to 96-well plates were pipetted under sterile conditions and OD 600 was measured with a microplate reader, 3 replicates per group.
Viable cell count determination: the assay was performed by gradient dilution-plate coating, 3 replicates per group.
The optimization experiment process is as follows:
Setting a certain range for each nutrient element affecting the growth and reproduction of lactobacillus, and optimizing conditions based on coconut water basic culture medium, wherein the nutrient elements are as follows: the sugar degree adding range is set to be 1, 2.5 and 4 degrees Bx; the peptone addition range is set to be 5, 10 and 15g/L; the adding range of the yeast extract powder is 1, 3 and 5g/L, the adding range of sodium acetate is 1, 3 and 5g/L, and the adding range of the citric acid triammonium is 0, 0.5, 1 and 1.5g/L. The viable count and turbidity of the bacterial liquid were measured after culturing at 37℃for 18 hours at an inoculum size of 2%.
As is clear from FIG. 8, when the sugar degree was 4℃Brix, the addition amount of yeast extract was 5g/L, the addition amount of peptone was 5g/L, the addition amount of sodium acetate was 5g/L, and the addition amount of triammonium citrate was 0.5g/L, the viable count was 1.8X10 8 CFU/mL, and the absorbance was about 1.25, which were all at or near the highest value. In terms of cost saving, the fermentation conditions were taken as those of the strain MS2c in coconut water medium.
In the embodiment, firstly, high-activity probiotics are screened from the intestinal tracts of Wenchang chickens, then 10 lactic acid bacteria including a laboratory pre-screened strain and a commercial control strain are subjected to in vitro antibacterial activity comparison to obtain lactobacillus plantarum MS111 and MS2c from the intestinal tracts of chickens and lactobacillus fermentum A32 from fermented foods, three lactic acid bacteria with higher antibacterial activity are screened through acid and bile salt tolerance re-screening, one lactobacillus plantarum MS2c is selected as a preferred strain, and the culture medium component of the strain MS2c is optimized, so that the viable count reaches more than 10 8 CFU/mL, the activity of the fermented coconut water metazoan is greatly improved, and a basis is provided for the subsequent application experiment on enteritis chickens. The research is to comprehensively utilize the byproduct coconut water, so that the coconut water becomes a culture medium suitable for lactobacillus plantarum fermentation, and a new thought and a new way are provided for grading treatment and efficient utilization of the coconut water.
Example 2 screening and identification of probiotic Yeast Y301
The strain has been deposited at the collection of microorganism strains (GDMCC) of Guangdong province at 12/24 of 2023 under the deposit number GDMCCNo:64183, deposit address: building 5, road 100, university, building 59, university of Guangzhou City martyr, university of Guangdong, institute of microorganisms, taxonomic designation: saccharomyces cerevisiae (Saccharomyces cerevisiae).
Separating and purifying strain
Naturally fermenting (at room temperature and 25-35 ℃ for more than 48h in an open container) coconut water in a coconut processing factory, taking a naturally fermented coconut water sample, fully and uniformly mixing, and then sucking 2mL as a bacteria screening sample to screen saccharomycetes with probiotic characteristics.
The natural fermentation coconut water sample is added into YPD culture medium to carry out enrichment culture at 30 ℃, and then is subjected to coating separation in coconut water solid culture medium by serial dilution method to carry out culture at 30 ℃. And (3) screening colony morphology of the single colonies, picking the single colonies to be larger, carrying out streak separation on the suspected saccharomycetes colonies again, picking out the single colonies to carry out microscopic examination, and carrying out YPD inclined plane preservation on the colonies judged to be saccharomycetes by budding propagation.
Second, microscopic examination of the strain
And selecting single colonies from the plate after streak purification, and observing the single colonies by a crystal violet single-staining method in a microscopic way to finally obtain 40 saccharomycete isolates which are all round, oval or sausage-shaped in form and all bud and reproduce. Subsequently, a coconut water liquid culture was carried out, and a culture which was capable of rapidly clouding coconut water but which had no floating film on the liquid surface was selected, and 7 strains were obtained, of which the morphology of strains Y301, S1171 and 134 was representative, and the colony and fungus morphology thereof were as shown in FIG. 9.
Screening of yeasts based on growth Properties in coconut Water
Screening fast growing strains according to the turbidity change speed of the bacterial liquid during the culture in coconut water, and selecting a plurality of strains for viable count: yeast was inoculated into 30mL of sterilized coconut water medium at an inoculum size of 2%, and fermented at 30℃for 15 hours, and the viable count was measured by plate viable count method, as shown in FIG. 10.
Statistical analysis showed that the viable count of strains Y301 and S1171 was significantly higher than the other strains (p < 0.05), and that strain 134 was also selected as an alternative strain.
Fourth, acidity and bile salt tolerance screening
Acid resistance culture experiment: liquid YPD medium was prepared, and pH was adjusted to 2.0, 3.0 and 4.0 with 1mol/L HCl, respectively, and a set of pH was set to be natural and non-adjusted. The yeasts obtained by the preliminary screening were inoculated at 2%, cultured at 30℃for 15 hours, and OD 600 values of each strain were measured.
Bile salt resistance experiment: the primary screening yeasts are inoculated into YPD liquid culture media with the concentration of bile salts of 0, 0.3%, 0.6% and 0.9%, respectively, and are cultured for 15 hours at 30 ℃, and OD 600 is measured. The survival rate of each strain was calculated as follows:
survival = Na/Nb x 100%, na is OD 600 value after application of treatment, nb is OD 600 without treatment (pH natural and without bile salts).
From the results of fig. 11, it was found that strain Y301 exhibited the highest acid resistance: the survival rate of Y301 was significantly higher than 134 and S1171 (p < 0.05) in different pH environments. At pH4, the survival rate of Y301 was highest, the difference was insignificant compared to the survival rate at pH3, and at pH2 the survival rate was halved but still around 40%, indicating that strain Y301 had a higher acid resistance. But the acid resistance of strains 134 and S1171 is significantly lower than Y301.
In the bile salt tolerance experiment, Y301 survival at 0.3% bile salt concentration is significantly higher than S1171 and 134 (p < 0.05) as reflected in figure 12. However, at both 0.6% and 0.9% bile salt concentration, the viability of the three strains was significantly reduced (p < 0.05). This suggests that the yeast is sensitive to bile salts, but the Y301 bile salt tolerance is highest among the three strains, so that the strain Y301 is to be selected as the target test strain for the subsequent chicken enteritis self-healing recovery test. In order to determine the species relationship, strain identification is performed first.
Fifth, species identification of Strain Y301
And (3) carrying out ITS sequencing identification on the strain Y301, wherein the ITS gene sequence 673bp is shown as SEQ ID NO. 2. The NCBI alignment was submitted, and the results are shown in Table 3, with the combination of morphological features, to comprehensively determine that strain Y301 was Saccharomyces cerevisiae (Saccharomyces cerevisiae).
TABLE 3 ITS gene sequence alignment of Strain Y301
Example 3 preparation of lactic acid bacteria and Yeast composite probiotic fermented coconut Water metaplasia and Process optimization
When the conditions are optimized below, the composite probiotics of lactic acid bacteria and saccharomycetes are fermented at the temperature of about 35 ℃. The fermentation temperature can be between 33 and 37 ℃ without affecting the fermentation effect.
Determination of the inoculation ratio of the fermentation of the Complex Strain
Referring to fig. 13, it can be found that substantially similar variation trend is exhibited by setting different inoculation ratios of lactobacillus and yeast, wherein when the ratio is lactobacillus: when the saccharomycetes are 1:2, the number of viable bacteria in the fermentation water of the compound strain reaches the highest, and the compound strain can be maintained for a longer time in a stable period and can be obviously higher than other ratios when being cultured in a compound way, and the total number of viable bacteria is 4.05X10 8 CFU/mL. Thus lactic acid bacteria were selected: yeast is 1:2, and is used as the inoculation ratio of the metazoan after the preparation of the compound strain fermented coconut water.
Determining the fermentation and inoculation sequence of the composite strain
From the inoculation sequence and viable bacteria count chart (FIG. 14), the viable bacteria count in the simultaneous inoculation mode was significantly higher than that of the other groups at the time points 18h, 24h, 30h and 36h, and the viable bacteria count was 2.62X10 8 CFU/mL. Therefore, the mode of simultaneous inoculation is selected, and the subsequent popularization and application are also facilitated.
Third, determination of total inoculation amount of composite strain fermentation
The effect of inoculum size on viable count is shown in FIG. 15, wherein 4% and 5% inoculum sizes are significantly higher than the other two groups, 4% of the groups are in 12-20 h, the viable count is extremely fast increased and reaches a level (p > 0.05) equivalent to 5% inoculum size, and the larger inoculum size can maintain good strain advantage of the target strain, and is beneficial to fast propagation in coconut water to inhibit infectious microbe, so 4% inoculum size is selected, and the viable count is 4. 10 8 CFU/mL. Determining the number of viable bacteria and fermentation time of single-strain fermentation and composite-strain fermentation
Based on the above screening experiments, fermentation conditions for different strains were set as follows: MS2c is inoculated into a sterilized coconut water culture medium according to the inoculation amount of 2 percent, and fermentation culture is carried out at 37 ℃; y301 was also inoculated in a sterilized coconut water medium at an inoculum size of 2%, and cultured by fermentation at 30 ℃; the composite strain is mixed in a ratio of 1:2, inoculated into sterilized coconut water culture medium according to a total inoculum size of 4 percent, and fermented and cultured at 35 ℃.
As can be seen by comparing trend graphs of single bacteria and composite strain fermentation (see FIG. 16), after 18 hours of single bacteria fermentation, the viable count reaches the highest value of 2.00×10 8 CFU/mL, while the viable count of composite strain fermentation is significantly higher than that of single bacteria fermentation (p < 0.05) after 18 hours, and still presents a slow rising trend after 24 hours and reaches the highest value of 2.86×10 8 CFU/mL after 30 hours, and can maintain a higher viable count level within 36 hours, which indicates that the composite culture of the two is favorable for significantly prolonging the stable period of the total viable count. Therefore, the optimal biomass time for single-strain fermentation of the saccharomycetes and the lactobacillus is determined to be 18h and 24h, and the optimal biomass time for single-strain fermentation of the compound strain is determined to be 24-30 h.
Therefore, through the experimental results, and based on the consideration of cost and efficiency, the optimal fermentation conditions for the composite fermentation are selected as follows: two bacteria are inoculated simultaneously, and lactic acid bacteria are used for: the yeast is in a ratio of 1:2, 4% of total inoculum size is used for fermenting coconut water by the compound strain, and the compound strain is prepared into a compound strain fermented coconut water metaplasia after being cultured for 24-30 hours at 35 ℃ and is prepared into a feed additive for further application experiments.
Test example production and self-healing promotion of post-natal element of coconut water fermented by probiotics on Wenchang chickens with DSS induced enteritis
In the present invention, animal experiments and protocols were approved by the university of Hainan ethical Committee and followed the guidelines of "university of Hainan laboratory animal protection and utilization guidelines (approval number HNUAUCC-2023-00210)".
Data analysis was performed using GraphPad (san diego, california, usa GraphPad Software) and R software. Data are presented as mean ± Standard Deviation (SD), significance is marked using the difference letters: at p <0.05, the differences between the letters were considered significant. In the partial large graph, the differences are represented significantly as: i.e. p <0.05; the difference is very significant expressed as: i.e. p <0.01; the most significant difference is expressed as: i.e. p <0.001.
Experimental methods and designs
Modeling experiment of chicken enteritis model: in order to fully study the effect of two probiotics on the self-healing recovery of the acute enteritis of poultry, we induced the acute enteritis in chickens. First, a modeling experiment was performed on 14-day-old chickens to evaluate the effect of two different concentrations (1.5% and 2.5% w/v) and two intake methods (gavage and free drinking) of Dextran Sodium Sulfate (DSS) on the chicken intestinal tract. The results showed that 14 day old chickens, who were free to drink 1.5% DSS solution, exhibited diarrhea symptoms, some also had bloody stool. At the same time, higher concentrations of 2.5% DSS solution caused more severe symptoms, a higher blood to stool ratio, and even death of individual chickens. Therefore, 1.5% DSS (w/v, 40,000kda, macklin) solution was selected for free drinking and modeling experiments were performed for 7 days to induce acute enteritis in the chickens tested.
The experimental process of constructing acute enteritis model chicken and fermenting coconut water metaplasia by probiotics comprises the following steps: 60 Wenchang chicken cocks with a day age of 2 weeks and a weight range of 90-110 g are purchased from Wenchang in Hainan province. Randomly dividing into six groups (n=10), and raising in a laboratory at 28-30 ℃ in chicken cages, wherein each group is fed with the recommended common feed of the breeding plant every day, and only the additives in drinking water are different. Adding 1.5% DSS solution, performing enteritis molding for 1 week, stopping using DSS after molding success, and entering into prebiotic intervention feeding experimental stage after fermenting coconut water by probiotics for 2 weeks. Each group is free to feed the same daily ration and purified water every day, but each group is fed with 2mL of corresponding solution every morning, and the specific conditions are as follows: blank control (CK 1) and model control (CK 2): purified water is provided; unfermented coconut water control group (CK 3): feeding 2mL of unfermented coconut water; feeding 2mL S.cerevisiae Y301 fermented coconut water into yeast group (Y3 group); the bacterial group (M2 group) is irrigated with 2mL L.plantarum MS2c fermented coconut water; the mix group (MY 5) was fed with L.plantarium and S.cerevisiae mix fermented coconut water. The experiment was ended after 2 weeks of intervention feeding, i.e. 21 days of total test time, weighed after 12 hours of fasting, and blood was collected from the winged vein while euthanasia was performed by neck bleeding. The sections of the intestinal tract and cecum stool specimens were opened and subjected to biochemical and immunological index measurement, intestinal microbiology diversity and cecum metabonomics analysis, and the simplified procedure is shown in fig. 17.
Second, growth performance, physiological and biochemical and immune index measurement
Physiological indicators are measured to assess the health differences in chickens, including daily ration intake, daily gain, and Disease Activity Index (DAI). Fecal occult blood levels were determined using a test kit. Blood samples of ten chickens from each group were collected before euthanasia, and serum was isolated after 30 minutes of natural clotting. Serum levels of cytokines IL-10, IL-6, TNF- α and IFN- γ were determined using ELISA kit (Solabo, beijing, china). Meanwhile, serum biochemical indexes including glutamic-oxaloacetic transaminase (GOT), glutamic-pyruvic transaminase (GPT), uric Acid (UA) and D-lactic acid (D-LA) were measured using a detection kit (Solabo, beijing, china).
2.1 Effect of prebiotic intervention of coconut Water fermentation by probiotics on growth performance recovery of acute enteritis model chickens
As shown in fig. 18, after 7 days of molding with DSS, all other groups, except the control group CK1, showed lower daily intake, preliminarily demonstrating that molding was effective. After the start of the intervention experiment, the rate of recovery of the ration intake was faster for MY5 and Y3 groups than for CK2, CK3 and M2 groups by day 12. Until the end of the full course experiment on day 21, the recovery of ration intake was higher for the MY5 and Y3 groups than for the M2, CK2 and CK3 groups. The average weight of the chickens and the feed intake tended to be similar. Demonstrating that the intervention of saccharomycete Y301 in fermented coconut water metazoans (Y3 group and MY5 group) is more beneficial to the weight recovery of the chickens with acute enteritis.
However, feed intake and weight gain tended to return well for the 3 coconut water metazoan intervention groups (Y3, M2, MY 5) compared to model group CK2, with the 3 groups returning faster than CK2 (fig. 18a and b). In addition, disease Activity Index (DAI), in particular scores associated with intestinal disease, are improved. And the observation of the conditions of stool color, humidity and the like in the test process shows that the prebiotic intervention after the fermentation of coconut water by probiotics effectively improves the abnormal stool, and the recovery speed of the conditions of stool such as loose stool, bloody stool, coccidian stool and the like is obviously faster than that of the CK2 group (figure 18 c).
2.2 Effect of prebiotic intervention of coconut Water fermentation by probiotics on the serum Biochemical and immune index of acute enteritis model chickens
The content of various cytokines and biochemical indexes in the serum of each group of 10 experimental chickens was determined by analysis (data average). The results (fig. 19) show that post-prebiotic intervention of probiotic fermented coconut water resulted in reduced levels of both serum inflammatory factors and anti-inflammatory factors. For the IL-10 index, the M2 and MY5 groups were significantly lower than the CK2 group (p < 0.05), with no significant difference (p > 0.05) from the control group CK 1. For the IL-6 index, MY5 group was significantly lower than CK2 group (p < 0.05), and M2 and Y3 groups were also reduced. As for the TNF-. Alpha.index, the level of Y3 group was significantly lower than that of CK2 group (p < 0.05). On the IFN-gamma index, the levels of M2, Y3 and MY5 groups were significantly lower than for the CK2 group (p < 0.05). It was found that the level of immune cytokines in serum correlated closely with the inflammatory response in chickens and was substantially consistent with the growth performance status (fig. 19 a).
The level of serum D-lactic acid (D-LA) can be used as a characteristic index of chicken intestinal mucosa injury and permeability increase. Experimental results showed that the CK2 group D-lactate levels were significantly higher than the probiotic intervention group Y3 and MY5 groups (p < 0.05). Indicating that the intervention of coconut water fermented by saccharomycete Y301 helps recovery of intestinal damage and reduces the level of D-lactic acid in serum. Uric Acid (UA) levels in serum can reflect kidney injury and load conditions. The serum uric acid difference between the model group and the control group is not obvious, which indicates that DSS modeling has little influence on the kidney and the function thereof. GOT and GPT enzymes are used as markers for assessing liver damage in chickens. Each probiotic fermented coconut water (M2, Y3, MY 5) significantly reduced GOT levels (p < 0.05) compared to control CK2 and inhibited GPT elevation in experimental chickens (fig. 19 b).
From comprehensive analysis, the influence rule trend of D-LA and IL-10 and IFN-gamma in the experiment is highly correlated, and the success of the modeling experiment is indirectly indicated. From the perspective of data trend, the probiotics intervention group effectively promotes the immune and biochemical indexes to develop towards good or obvious change direction, and the experimental group promotes the strengthening of intestinal immune biochemical indexes and barrier functions, thereby promoting the self-healing recovery process of acute enteritis inflammation induced by DSS.
Third, pathological index measurement
After the blood sampling experiment, the cecum 1cm section at the end of the intestine was retrieved. This section was used to evaluate cecal wall thickness and structural integrity, as observed by HE staining. The intestinal tissue of the chicken was treated according to the method of O.Srinal for staining and the cecal tissue was fixed with 4% (w/v) formaldehyde for 24 hours. Followed by dehydration, paraffin embedding, and cutting into 3 μm sections. Colon samples were stained for Hematoxylin and Eosin (HE) as described previously. Histopathological conditions were assessed using an optical microscope (Nikon, japan) and the extent of tissue damage was analyzed using Image-Pro Plus 6.0 analysis software and the results were reported in millimeters.
Histological examination of the ileum by HE staining (fig. 20, left) revealed that DSS-induced acute enteritis group (CK 2 group) resulted in severe ileal epithelial cell loss, villus structural destruction and massive villus fragmentation shedding. However, after two weeks of intervention of the prebiotics after fermentation of coconut water by probiotics, the intestinal mucosal structure of the experimental group (M2, Y3, MY 5) developed towards improvement. According to the results of fig. 20 (right), the approach between MY5 group and control group was close, without significant difference in intestinal wall thickness (p > 0.05). This shows that the MS2c and Y301 composite strain fermented coconut water metazoan has a remarkable recovery promoting effect on the damaged intestinal wall of the acute enteritis chicken. The intestinal wall thickness of the Y3 and M2 groups, although not yet fully recovered, was significantly lower than that of the control group (CK 1), but significantly higher than that of the model group (CK 2). Indicating that intervention of single strain fermented coconut water metazoans also helps to restore impaired intestinal wall structure.
Extraction and analysis of microbial diversity of the content of the cecum of chickens
After euthanasia, six chickens were randomly selected from each group and the cecal content was rapidly extracted. The cecum content samples were mixed and stored in dry ice and sent to the Shanghai Meiji biomedical technology Co., ltd for cecum microorganism diversity analysis. Analysis high throughput sequencing involving DNA extraction, PCR amplification of the V3-V4 variable region of the 16S rDNA gene, library construction and 16S functional predictive analysis.
The upstream primer used was 338F (5'-ACTCCTACGGGAGGCAGCAG-3') and the downstream primer was 806R (5 '-GGACTACHVGGGTWTCTAAT-3'). The 16S rDNA gene V3-V4 variable region of the sample was amplified by PCR, and the PCR reaction system was as follows: 5X TRANSSTART FASTPFU buffer 4. Mu.L, 2.5mM dNTPs 2. Mu.L, upstream primer (5. Mu.M) 0.8. Mu.L, downstream primer (5. Mu.M) 0.8. Mu.L, TRANSSTART FASTPFU DNA POLYMERASE 0.4. Mu.L, template DNA 10ng was adjusted to 20. Mu.L. Three replicates were prepared for each sample.
4.1 Effect of prebiotic intervention of coconut Water fermentation by probiotics on intestinal microbiota diversity and flora composition of acute enteritis model chickens
The present invention determines the microbial diversity of the experimental chicken cecal content by high throughput sequencing and analyzes the alpha diversity and beta diversity (fig. 21a and b), finding that there is a very significant difference in alpha diversity between CK1 and CK2 groups (p < 0.01). This shows that DSS modeling (CK 2 group) significantly reduced the microbiota diversity of the cecal contents of chickens, which again indirectly demonstrated the success of modeling experiments, with confidence in all experimental data and analytical results. While the microbial community α diversity of all experimental groups had a good trend (fig. 21 a), demonstrating that the intervention of the prebiotics after fermentation of coconut water by probiotics could play a role in intestinal microbial diversity recovery and protection. No significant differences were shown between the six groups of samples in terms of β diversity, indicating that the differences in microbial community structure at the genus level between these test groups were not large by 2 week time intervention. Some differences were still observed between the intervention group and model group CK2, and were further analyzed below.
After analyzing the relative abundance of each group of microorganism composition (FIG. 22), it was found that Bacteroides, faecalis, ruminococcus, bifidobacterium, majoranferae, odormitomyces, paralobacter, shigella and the like exert an important effect in the intestinal microorganism structure. Shigella coli is a common pathogenic bacterium, and results in bacillary dysentery, the content of M2 and MY5 groups (accounting for 0.3% and 0.16% respectively) is lower than the abundance in CK1 (2.7%) and Y3 (3.6%), which indicates that the relative content of parent pathogenic bacteria which exist in a certain amount (CK 1 group accounting for 2.7%) can be reduced when MS2c intervenes, and the potential improvement of the functions of intestinal flora structures is predicted.
In the group analysis chart (fig. 23C), it can be seen that bacteroides multinomial (Bacteroides dorei) is more abundant in the three control CK1, CK2 and CK3 groups and relatively lower in the CK2 group, which is a beneficial bacterium that can effectively break down carbohydrates into glucose and other sugars, helping digestion and absorption of nutrients from the feed. The second important gut is the gram negative another genus (ALISTIPES), which is reported to be positively associated with certain intestinal diseases, with a high abundance in the CK2 group. On the other hand, the abundance of lactococcus taiwanensis (Lactococcus taiwanensis), kriging Teng Senshi family R7 group (CHRISTENSENELLACEAE R group) was significantly higher in the control CK1 group and CK3 (p < 0.01), and lower in CK 2. Lactococcus taiwanensis is a potential probiotic commonly used for fermentation of dairy products; the bacteria kries Teng Senshi are reported to be inversely related to intestinal diseases. These data indicate that, after DSS treatment, CK2 group is used as model group of acute enteritis, and intestinal bacteria feelings of the masses condition corresponds to the detection result of clinical manifestation, immunology and histological index in the culture. Meanwhile, the intestinal tracts of Wenchang chickens are sensitive to DSS-induced intestinal flora imbalance, so that the DSS induction is a simple and effective enteritis model modeling method of the Wenchang chickens.
For the analysis of the M2 group, the heat map (fig. 23D) showed that the abundance of the cladosporium (ALISTIPES) highly correlated with intestinal disease was higher in the model group, whereas the abundance in the M2 group was lower, close to the control group, indicating that intervention by lactobacillus plantarum MS2c could effectively reduce the abundance of the potentially harmful bacteria cladosporium in the cecum of chickens. In addition, the comparison analysis of CK1 and CK2 groups shows that the abundance of the FSC020 group (Lachnospiraceae FSC020 group) and the Lactobacillus plantarum (L.plantarum) in the M2 group is higher than that of the model group, and even the abundance of the Lactobacillus plantarum is higher than that of the CK1 group, so that the MS2c intervention can cause the chicken intestinal tract to better colonize, thereby effectively increasing the abundance of beneficial Lactobacillus plantarum in the intestinal tract, repairing unbalanced intestinal flora and promoting the self-healing recovery of enteritis. The high abundance results of lactobacillus plantarum also highly correspond to the screening results of the multiple probiotics in the embodiment 1, and prove that the invention has high reliability and strong innovation in research content.
For group Y3, the heat map (fig. 23E) shows that the relative abundance of the other clade in the saccharomyces cerevisiae Y301-interfered group is lower than that of the model group, and is close to that of the control group. Whereas the group R7 of the family Krilsieidae Teng Senshi and the group NK3A20 of the family Maspiriaceae (Lachnospiraceae NK A20 group) were less abundant in model group CK2, but significantly more abundant in group Y3, which was closer to control group CK1. The intervention of the saccharomycete Y301 is also beneficial to the balance and recovery of intestinal flora in enteritis chickens.
For MY5 group, fig. 23F shows: the abundance of the krigineus Teng Senshi mycological R7 group in the model group CK2 is significantly lower than that of the control group CK1, and the group MY5 shows higher relative abundance and is closer to the control group, which indicates that the intestinal microbiomes of the CK1 group and the MY5 group are more stable. The abundance of the group NK3A20 in the trichomonadaceae is lower in the model group CK2, but the abundance of the group MY5 is obviously higher and is closer to the group CK 1. The bacillaceae is a genus that is known to produce short chain fatty acids and is inversely related to acute enteritis, with higher abundance in CK1 and MY5 groups than in CK 2. This suggests that the intestinal microbiome of the MY5 group is more similar to a healthy intestinal microbiome. Lactiplantibacillus plantarum also tended to be more abundant in the MY5 group than CK2 and CK1, suggesting that complex strain fermentation of coconut water post-primordial intervention is beneficial for colonization and stabilization of beneficial bacteria in the chicken gut microbiome.
Metabonomics determination and analysis of the content of the cecum of chickens
5.1 Effect of prebiotic intervention of coconut Water fermentation by probiotics on the metabolites of the content of the cecum of acute enteritis model chickens
As shown in FIG. 24, principal Component Analysis (PCA) was performed on the integrated data for each group of metabolites, and the results showed that the metabolites of the different groups aggregated together, indicating a high similarity between models. However, by performing partial least squares-discriminant analysis (PLS-DA) on each experimental group, it was found that the experimental groups M2 and MY5 were separated from the model group CK2 at a higher degree, as in the control group CK1, and showed a significant difference (p < 0.05), which indicates that the intervention of coconut water fermented with lactic acid bacteria MS2c was able to significantly recover the metabolites in the intestinal tract to the near control group. On the other hand, the degree of separation between CK3 group, Y3 group and model group CK2 was relatively low, indicating limited effect on intestinal metabolites after intervention of unfermented coconut water group (CK 3) and yeast fermented water alone (Y3). This also suggests that the intervention of strain MS2c in fermenting coconut water metazoans may be a major factor in the differentiation of intestinal metabolites, suggesting that probiotic MS2c has intrinsically better regulatory efficacy of the metabolites in improving intestinal flora balance and repair.
5.2 Path analysis of intestinal metabolism in model enteritis chickens by prebiotic intervention in coconut Water fermentation by probiotics
In the topology, the horizontal axis represents importance, and the vertical axis represents p-value. Metabolic pathways with p-values less than 0.05 were selected for analysis, with the most important of the key pathways identified as affecting the relevant metabolite concentration or activity. In the case of the lactobacillus MS2c intervention (group M2), the key metabolic pathway with the most significant difference was glycerophospholipid metabolism (fig. 25, left), suggesting that possibly the intestinal wall mucosal cells of the enteritis model chickens were stimulated by the intestinal beneficial metabolites to be repaired faster and better. In the case of the intervention of the yeast Y301 (group Y3), the main pathways affecting the differences in metabolites include alanine, aspartic acid and glutamic acid metabolic pathways (fig. 25, right), in which alanine is an important precursor substance of bile acids, aspartic acid is mainly digested and metabolized in the liver to produce urea and supply energy to the body, and glutamic acid can form α -ketoglutarate with pyruvic acid, participating in the regulation of tricarboxylic acid cycle, having an effect on both energy metabolism and substance metabolism in chicken digestion.
5.3 Correlation analysis between differential flora and differential metabolites
Correlation analysis of differential metabolites and differential flora (fig. 26 a) showed a significant negative correlation between MS2c intervention (M2 group) and ALISTIPES genus. There are several reports showing ALISTIPES to exhibit pathogenic characteristics in enteritis and bowel cancer. The invention discovers that MS2c fermented coconut water metaplasia can reduce the abundance of ALISTIPES in cecum, and further supports the repair or inhibition effect of the metaplasia on intestinal inflammation. In addition, a negative correlation was observed between MS2c fermented coconut water metazoan and epsilon-caprolactam, which was classified by the WHO as one of the 4 classes of carcinogens. This suggests that the strain MS2c of the present invention fermented coconut water metazoan may have an inhibitory effect on the production of certain potentially carcinogenic compounds in the chicken intestinal tract, thereby advantageously promoting the recovery of intestinal health.
In the analysis of differential metabolites and differential bacteria of intestinal contents, several substances were found to be positively correlated with MS2c fermented coconut water metazoans, which are CHRISTENSENELLACEAE, DESULFUROCOCCUS, gentamicin gentamicin) C, CDP-DG (a-25:0/a-21:0), lachnospiraceae, polymyxin (polymyxin) B2, berberine (berberine) and Botrytis halophila (halophilic arcobacter), and the like. Of these, CHRISTENSENELLACEAE, known for its negative correlation with inflammation, is a bacterial family with potential probiotic properties, and Lachnospiraceae promotes intestinal health by metabolizing short chain fatty acids.
In the correlation analysis of group Y3 (FIG. 26 b), 5-methoxytryptophan was positively correlated with ALISTIPES. This may be due to its role in the signalling pathway, leading to an increase in its level in the gut in severe inflammation.
Sixth, promote the probiotic intervention mechanism that acute enteritis model chicken resumes
Through the comprehensive analysis of the series of related indexes and intestinal flora and metabolite data, two potential mechanisms for promoting acute enteritis recovery are revealed. After passing MS2c fermented coconut water metazoans through 2 weeks of drinking water for dry prognosis, the following key changes were observed:
first, the daily ration intake, weight gain and DAI values of enteritis chickens are all trended well after intervention. Meanwhile, the abundance of beneficial bacteria in the intestinal tract, such as lactobacillus plantarum, CHRISTENSENELLACEAE, LACHNOSPIRACEAE, bifidobacterium ragum and the like, is increased, and the intestinal microecological balance is maintained.
Secondly, the MS2c intervention reduces the level of D-lactic acid and GOT enzyme in the serum of enteritis chickens, and reduces IL-10 and IL-6 indexes and TNF-alpha and IFN-gamma indexes of the enteritis chickens. These indicators are all associated with DSS-induced intestinal inflammation, and a decrease in the level of the indicator indicates that the intervention is effective and helps to reduce the inflammatory response.
Again, MS2c intervention also reduced the abundance of the potentially pathogenic ALISTIPES genera associated with colon cancer in the gut. More importantly, the intervention increased the levels of the beneficial metabolites gentamicin C, polymyxin B2 in the gut. These metabolites play an important role in promoting inflammatory recovery and maintaining intestinal health (fig. 27 a).
In addition, MS2c intervention affects the glycerophospholipid metabolic pathway, resulting in increased CDP-DG (a-25:0/a-21:0) levels, potentially stimulating rapid repair of intestinal mucosal cells, reducing intestinal inflammation.
An increase in abundance of Lachnospiraceae families was indirectly observed due to intervention of the metazoan of Y301 fermented coconut water. These bacteria can produce probiotic metabolites such as short chain fatty acids, inhibiting the growth of ALISTIPES genus associated with inflammation. This change resulted in increased abundance of anti-inflammatory and inflammation-reducing compounds such as melatonin, deoxyinosine, lauroyl glycine, guanidinopropionic acid, and methyltryptophan (fig. 27 b).
In addition, intervention of Y301 reduces the levels of pro-inflammatory metabolites such as tetradecanoic acid, thereby reducing the levels of intestinal inflammatory factors including TNF- α, IFN- γ, and D-lactic acid. This series of changes affects the alanine, aspartate and glutamate metabolic pathways, increasing the levels of methyltryptophan and melatonin, thereby enhancing the antioxidant capacity of the gut and maintaining gut health.
Thus, the findings of the present application suggest that the intervention feeding of probiotic fermented coconut water may help to promote slow recovery of chickens from acute enteritis. Relevant data results of improving physical, biochemical and immunological barriers of intestinal tracts are observed, thereby helping recovery of Wenchang chickens in DSS induced acute enteritis.
In conclusion, the study of the invention shows that the metazoan formed by probiotics and fermented coconut water has positive effects on the recovery of acute enteritis of Wenchang chickens: saccharomyces CEREVISIAE Y301 regulates amino acid metabolism, results in higher levels of melatonin, promotes cell proliferation and development, intervenes to improve chicken growth rate, lactiplantibacillus plantarum MS c intervenes to regulate glycerophospholipid metabolic pathways, remodels intestinal flora structure of acute enteritis chicken, reduces the abundance of potential pathogenic bacteria of ALISTIPES genus, and increases the abundance of potentially beneficial species such as L.plantarum, CHRISTENSENELLACEAE, and the like. But also results in the production of beneficial intestinal metabolites such as gentamicin C and polymyxin B2, which are recognized for their therapeutic effect on acute enteritis. The combined intervention of S.cerevisiae Y301 and L.plantarum MS2C not only enhances the growth performance, but also reduces the damage of intestinal walls, and increases the abundance of intestinal metabolites such as gentamicin C, polymyxin B2 and the like, thereby reducing enteritis symptoms. In addition, this combined intervention also reduced serum immune marker levels, including IL-10, IL-6, TNF- α, IFN- γ and D-lactate, thereby alleviating intestinal epithelial cell damage and promoting recovery from acute enteritis. The research provides important insights for probiotics and the action mechanism of the coconut water fermented by the probiotics in recovery of acute enteritis, and provides a new view for sustainable green cultivation practice of Wenchang chickens.
It should be understood that the foregoing examples of the present invention are merely illustrative of the present invention and not limiting of the embodiments of the present invention, and that various other changes and modifications can be made by those skilled in the art based on the above description, and it is not intended to be exhaustive of all the embodiments of the present invention, and all obvious changes and modifications that come within the scope of the invention are defined by the following claims.
Claims (6)
1. A novel probiotic lactic acid bacterium, named lactobacillus plantarum (Lactiplantibacillus plantarum) MS2c, deposit No. GDMCC No:64184.
2. A novel probiotic yeast, named Saccharomyces cerevisiae (Saccharomyces cerevisiae) Y301, accession number GDMCC No:64183.
3. The prebiotics of the coconut water fermented by the probiotics are selected from lactobacillus fermented coconut water prebiotics which take lactobacillus MS2c single bacteria as fermentation strains, or saccharomycetes fermented coconut water prebiotics which take saccharomycetes Y301 single bacteria as fermentation strains, or compound bacterial strains fermented coconut water prebiotics which take lactobacillus MS2c and saccharomycetes Y301 together as fermentation strains; the lactobacillus MS2c has a preservation number of GDMCC No:64184; the preservation number of the saccharomycete Y301 is GDMCC No:64183.
4. A method for preparing a prebiotic after fermentation of coconut water by probiotics, comprising: simultaneously inoculating lactobacillus MS2c and saccharomycete Y301 according to the following lactobacillus: the yeast is in a ratio of 1:2, 4% of total inoculum size is used for fermenting fresh coconut water by the composite strain, the fermentation temperature is 33-37 ℃, and the fermentation time is 24-30 hours; the lactobacillus MS2c has a preservation number of GDMCC No:64184; the preservation number of the saccharomycete Y301 is GDMCC No:64183.
5. A poultry feed additive comprising the probiotic fermented coconut water metazoan of claim 3.
6. Use of the probiotic fermented coconut water metazoan of claim 3 in the manufacture of a medicament for use in the growth and promotion of self-healing recovery of enteritis in birds, such as Wenchang chickens.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410122547.2A CN118028155B (en) | 2024-01-30 | 2024-01-30 | Novel probiotics, fermented coconut water metaplasia and application thereof in poultry feed additive |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410122547.2A CN118028155B (en) | 2024-01-30 | 2024-01-30 | Novel probiotics, fermented coconut water metaplasia and application thereof in poultry feed additive |
Publications (2)
Publication Number | Publication Date |
---|---|
CN118028155A CN118028155A (en) | 2024-05-14 |
CN118028155B true CN118028155B (en) | 2024-09-06 |
Family
ID=90996081
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410122547.2A Active CN118028155B (en) | 2024-01-30 | 2024-01-30 | Novel probiotics, fermented coconut water metaplasia and application thereof in poultry feed additive |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118028155B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN118556650A (en) * | 2024-08-05 | 2024-08-30 | 新昌县天姥实验室 | Construction and evaluation methods and application of DSS-induced intestinal inflammation injury animal model |
CN118581016B (en) * | 2024-08-05 | 2024-11-01 | 苏州安迈康生物科技有限公司 | Probiotic agent for regulating intestinal flora of poultry and preparation method and application thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106721021A (en) * | 2016-12-30 | 2017-05-31 | 长春禾丰饲料有限责任公司 | A kind of piglet antibiotic-free feed and preparation method thereof |
BR112020022749A2 (en) * | 2018-05-09 | 2021-03-02 | Ko Biolabs, Inc. | strain of lactobacillus paracasei and its use |
CN111480752A (en) * | 2019-01-29 | 2020-08-04 | 内蒙古伊利实业集团股份有限公司 | Fermented coconut water beverage base material, fermented coconut water beverage and preparation method thereof |
KR102275115B1 (en) * | 2019-10-16 | 2021-07-07 | 한국식품연구원 | Novel Saccharomyces cerevisiae boulardii-03 strain having probiotic activities and use of the same |
KR102315134B1 (en) * | 2019-11-25 | 2021-10-20 | (주) 바이텍 | Fermented kiwi powder for improving bowel function and method of preparing the same |
CN111281895A (en) * | 2019-12-24 | 2020-06-16 | 顾青 | Lactic acid bacteria for treating colitis and application thereof |
CN112708568B (en) * | 2021-01-29 | 2023-03-21 | 上海理工大学 | Saccharomyces cerevisiae with function of relieving acute colitis |
KR102620909B1 (en) * | 2022-06-15 | 2024-01-04 | 콜마비앤에이치 주식회사 | Novel Lactiplantibacillus plantarum SKO-001 and use thereof |
CN115851500B (en) * | 2022-09-23 | 2024-04-02 | 四川大学 | Lactobacillus plantarum and application thereof |
CN116688019B (en) * | 2023-08-03 | 2024-05-03 | 仙乐健康科技股份有限公司 | Litchi fermentation product for improving fecal occult blood and intestinal barrier and regulating intestinal flora |
CN117322568A (en) * | 2023-09-27 | 2024-01-02 | 广州市果美味食品有限公司 | Strong-flavor coconut water and preparation method thereof |
-
2024
- 2024-01-30 CN CN202410122547.2A patent/CN118028155B/en active Active
Non-Patent Citations (1)
Title |
---|
Lactiplantibacillus plantarum and Saccharomyces cerevisiae—Fermented Coconut Water Alleviates Dextran Sodium Sulfate-Induced Enteritis in Wenchang Chicken: A Gut Microbiota and Metabolomic Approach;Leijie Zheng等;Animals;20240208;第14卷(第4期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN118028155A (en) | 2024-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN118028155B (en) | Novel probiotics, fermented coconut water metaplasia and application thereof in poultry feed additive | |
CN105132322B (en) | One lactobacillus plantarum and application thereof | |
CN102453689B (en) | Lactobacillus plantarum strain producing extracellular polysaccharide, and application thereof | |
CN109055268B (en) | Composite microecological preparation and application thereof in bee breeding process | |
CN109182165B (en) | Lactobacillus helveticus strain and application thereof in bee breeding process | |
Al-Thubiani et al. | The Prebiotic Properties of Date Palm (Phoenix dactylifera L.) Seeds in Stimulating Probiotic Lactobacillus. | |
CN109666614B (en) | Lactobacillus rhamnosus and application thereof in preparing health food and medicine for preventing allergic asthma | |
CN109182164B (en) | Lactobacillus reuteri strain and application thereof in bee breeding process | |
CN110157645B (en) | Lactobacillus salivarius Y4 and application thereof | |
CN114381395B (en) | Lactobacillus plantarum ZJFFN 1 and application thereof | |
CN110106119A (en) | The Lactobacillus rhamnosus M9 of one plant of isolated from mother's milk and its application | |
CN114686402A (en) | Lactococcus lactis subsp lactis HFY14 and application thereof | |
CN116286551A (en) | Application of bifidobacterium longum subspecies infantis in regulating in-vivo fat metabolism, shaping, reducing fat and improving obesity | |
CN116396890B (en) | Lactobacillus plantarum ZJUIDS15 for preventing and treating colon cancer and application thereof | |
CN110028560B (en) | Bacteriocin produced by bacillus coagulans and application thereof | |
CN116121122A (en) | Probiotic composite preparation for preventing and treating diarrhea of cats and application thereof | |
KR101201420B1 (en) | A feed additive containing novel Lactobacillus jonhsonnii | |
CN117327616A (en) | Lactiplantibacillus plantarum ZN1 and application thereof | |
CN115466693B (en) | Stokes Bei Jisi Rumex bacillus CY2 strain and application thereof | |
CN116987645A (en) | Lactobacillus plantarum (Lactiplantibacillus plantarum) HEPRO-185 and application thereof | |
CN117660218A (en) | Lactobacillus reuteri LR108 strain capable of improving obesity of dogs and cats and application thereof | |
CN105624071A (en) | Lactobacillus salivarius XJP2 and application thereof | |
CN113913334B (en) | Enterococcus faecalis EF-ZA1107-06 and application thereof | |
CN110463824B (en) | Lactobacillus austenitic strain BSLO1801 and application thereof in laying hens | |
CN109161501B (en) | Feeding bacillus licheniformis and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |